MX2023009352A - Metodos para la administracion oftalmica de roflumilast. - Google Patents

Metodos para la administracion oftalmica de roflumilast.

Info

Publication number
MX2023009352A
MX2023009352A MX2023009352A MX2023009352A MX2023009352A MX 2023009352 A MX2023009352 A MX 2023009352A MX 2023009352 A MX2023009352 A MX 2023009352A MX 2023009352 A MX2023009352 A MX 2023009352A MX 2023009352 A MX2023009352 A MX 2023009352A
Authority
MX
Mexico
Prior art keywords
eye
roflumilast
cornea
tissues
methods
Prior art date
Application number
MX2023009352A
Other languages
English (en)
Spanish (es)
Inventor
Bhaskar Chaudhuri
Hovhannes John Gukasyan
Original Assignee
Iolyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iolyx Therapeutics Inc filed Critical Iolyx Therapeutics Inc
Publication of MX2023009352A publication Critical patent/MX2023009352A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2023009352A 2021-02-10 2022-02-10 Metodos para la administracion oftalmica de roflumilast. MX2023009352A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163148008P 2021-02-10 2021-02-10
US202163261404P 2021-09-20 2021-09-20
PCT/US2022/015942 WO2022173923A1 (en) 2021-02-10 2022-02-10 Methods for ophthalmic delivery of roflumilast

Publications (1)

Publication Number Publication Date
MX2023009352A true MX2023009352A (es) 2023-08-16

Family

ID=82704332

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009352A MX2023009352A (es) 2021-02-10 2022-02-10 Metodos para la administracion oftalmica de roflumilast.

Country Status (8)

Country Link
US (2) US12102622B2 (cg-RX-API-DMAC7.html)
EP (1) EP4291162A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024506384A (cg-RX-API-DMAC7.html)
AU (1) AU2022218993A1 (cg-RX-API-DMAC7.html)
CA (1) CA3206106A1 (cg-RX-API-DMAC7.html)
IL (1) IL304924A (cg-RX-API-DMAC7.html)
MX (1) MX2023009352A (cg-RX-API-DMAC7.html)
WO (1) WO2022173923A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12263160B2 (en) * 2021-09-22 2025-04-01 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases
AR130498A1 (es) * 2022-09-16 2024-12-11 Iolyx Therapeutics Inc Composiciones farmacéuticas de alta concentración de roflumilast para administración oftálmica
AU2024298631A1 (en) * 2023-07-25 2026-02-05 Iolyx Therapeutics, Inc. Ocular surface topical administration of roflumilast for treatment of anterior and retinal-vitreous chamber ocular diseases

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ290266B6 (cs) 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
SK122199A3 (en) 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
BR0013793A (pt) * 1999-09-06 2002-05-14 Ono Pharmaceutical Co Medicamentos profiláticos e terapêuticos para doenças oftálmicas
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
JP3805203B2 (ja) * 2001-02-16 2006-08-02 日本油脂株式会社 点眼用水性懸濁製剤およびその製造方法
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
IL160271A0 (en) 2001-09-19 2004-07-25 Altana Pharma Ag Pharmaceutical compositions containing pde4-inhibitors and nsaid
US20060084684A1 (en) * 2002-05-28 2006-04-20 Altana Pharma Ag Topically applicable pharmaceutical preparation
US20060263350A1 (en) 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
WO2006028618A1 (en) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
NZ585697A (en) 2004-08-02 2011-12-22 Univ Virginia Patent Found 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
DE102004046235A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
ES2421916T3 (es) * 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast
SI1885336T1 (sl) 2005-05-10 2009-08-31 Alcon Inc Suspenzijske formulacije, ki obsegajo aktivno sestavino, poloksamerni ali meroksapolni surfaktant in glikol, in njihova uporaba za pripravo zdravila za zdravljenje oftalmičnih motenj
AU2006244245B2 (en) 2005-05-10 2010-11-18 Alcon, Inc. Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
JP2007016024A (ja) * 2005-06-09 2007-01-25 Santen Pharmaceut Co Ltd ロフルミラスト点眼液
WO2006132342A1 (ja) * 2005-06-09 2006-12-14 Santen Pharmaceutical Co., Ltd. ロフルミラスト点眼液
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
DK2250161T3 (da) 2008-01-18 2014-01-27 Atopix Therapeutics Ltd Forbindelser med CRTH2-antagonistaktivitet
CN103508936A (zh) 2008-08-22 2014-01-15 赛诺菲-安万特 用于制备吲哚苄胺化合物的中间体
MX2012006401A (es) 2009-12-03 2012-07-10 Lupin Ltd Proceso para preparar composiciones oftalmicas farmaceuticas.
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
AU2012232658B2 (en) 2011-03-22 2016-06-09 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
JP6363506B2 (ja) * 2011-11-15 2018-07-25 アラーガン、インコーポレイテッドAllergan,Incorporated シクロスポリンa2型の懸濁剤
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
HK1214159A1 (zh) 2012-11-08 2016-07-22 Rhizen Pharmaceuticals S.A. 含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
WO2015132708A1 (en) 2014-03-07 2015-09-11 Torrent Pharmaceuticals Limited Pharmaceutical composition of roflumilast
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
TW201729810A (zh) 2015-10-26 2017-09-01 札爾科製藥公司 嘧啶組成物、其超純組成物及鹽類、製造彼之方法、及使用彼於治療組織胺h4受體(h 4 )仲介之疾病與病情之方法
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
WO2020081622A1 (en) 2018-10-16 2020-04-23 Research Triangle Institute Subcutaneous biodegradable reservoir device
EP4061332A4 (en) 2019-11-24 2023-11-29 Sol-Gel Technologies Ltd. TREATMENT OF SKIN DISEASES USING TOPICAL COMPOSITIONS CONTAINING TAPINAROF AND A PDE4 INHIBITOR
US12263160B2 (en) * 2021-09-22 2025-04-01 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases

Also Published As

Publication number Publication date
IL304924A (en) 2023-10-01
US20220249451A1 (en) 2022-08-11
WO2022173923A1 (en) 2022-08-18
JP2024506384A (ja) 2024-02-13
US20250009724A1 (en) 2025-01-09
CA3206106A1 (en) 2022-08-18
US12102622B2 (en) 2024-10-01
EP4291162A1 (en) 2023-12-20
AU2022218993A1 (en) 2023-08-03
EP4291162A4 (en) 2024-12-11

Similar Documents

Publication Publication Date Title
Bengani et al. Steroid-eluting contact lenses for corneal and intraocular inflammation
AU2011282683B2 (en) Preservative free brimonidine and timolol solutions
KR20140076587A (ko) 노안, 경도 원시 및 불규칙한 난시의 치료를 위한 조성물 및 방법
JP6014033B2 (ja) 防腐剤無添加ビマトプロストおよびチモロール溶液
CA3095073A1 (en) Sap and peptidomimetics for treatment of eye disease
Polat et al. Combined phacoemulsification and trabectome for treatment of glaucoma
US10279046B2 (en) Eye drop composition for treating ocular inflammatory disease and preparation method therefor
JP2024506384A5 (cg-RX-API-DMAC7.html)
JP2009515921A (ja) デクスパンテノール、カルシウムイオン、およびリン酸塩を含まない薬学的組成物、ならびにカルシウムキレート剤および眼科的に適合性の粘性調節剤の使用
JPWO2018074421A1 (ja) 眼科用剤及び眼科用薬
JP2022541854A (ja) 老視の治療のための組成物および方法
AU2011282679A1 (en) Preservative free bimatoprost solutions
WO2018144909A1 (en) Ophthalmic compositions for therapeutic and prophylactic uses
CN106943590B (zh) 一种包含ngf的用于治疗角膜上皮损伤的药物组合物
WO2019054960A3 (en) Improving ophthalmic telomerase activity via topical and local ocular applications and preventing, delaying and / or treating impairments or diseases experienced due to degenerative processes (such as aging)
CA2453442A1 (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
Kassumeh et al. Corneal stromal filler injection as a novel approach to correct presbyopia—An ex vivo pilot study
LÁSER et al. Post-traumatic cyclodialysis cleft treated with transscleral diode laser
BR112023004851A2 (pt) Emulsões óleo em água para administração intravítrea
US20190099401A1 (en) Method for protecting corneal endothelial cells from the impact caused by an eye surgery
WO2020138135A1 (ja) 眼科用組成物
Galeana Pharmacologic compound to mitigate presbyopia symptoms
Makhzoum et al. Secondary angle-closure glaucoma due to posterior synechiae formation following phacovitrectomy
HOXHA Comparison of latanoprost 0.005% and travoprost 0.004% in patients with primary open angle glaucoma and ocular hypertension
Yoshino et al. Residual amounts of ophthalmic viscosurgical devices on the corneal endothelium following phacoemulsification